Omalizumab May Help Desensitization for Food Allergies Omalizumab May Help Desensitization for Food Allergies
A pilot study suggests omalizumab may improve speed, effectiveness, and safety of oral desensitization in children with multiple food allergies; more research is needed to see if effect lasts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 12, 2017 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
Omalizumab improves efficacy of oral immunotherapy for multiple food allergies
(NIH/National Institute of Allergy and Infectious Diseases) Combining a 16-week initial course of the medication omalizumab with oral immunotherapy (OIT) greatly improves the efficacy of OIT for children with allergies to multiple foods, new clinical trial findings show. After 36 weeks, more than 80 percent of children who received omalizumab and OIT could safely consume two-gram portions of at least two foods to which they were allergic, compared with only a third of children who received placebo and OIT. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2017 Category: International Medicine & Public Health Source Type: news
Intranasal Omalizumab Does Not Increase Serum IgE Levels
No relevant change in allergen - specific/total IgE levels for subjects challenged with omalizumab (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - November 22, 2017 Category: Respiratory Medicine Tags: ENT, Pharmacy, Pulmonology, Allergy, Journal, Source Type: news
Omalizumab Benefits Patients With Chronic Inducible Urticaria Omalizumab Benefits Patients With Chronic Inducible Urticaria
The recombinant anti-immunoglobulin E (IgE) monoclonal antibody omalizumab has ' substantial benefits ' in treating various forms of chronic inducible urticaria (CIndU), according to a new systematic review.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 11, 2017 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news
Omalizumab Response Varies by Asthma Type Omalizumab Response Varies by Asthma Type
Patients with specific phenotypes of severe asthma derive greater benefit from the biologic treatment than others, a multicenter, retrospective study shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
Omalizumab Protects Against Early, Late Allergic Responses
Significant reduction in early allergic reaction after 4 weeks, with decrease in FEV1, exhaled nitric oxide (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - June 9, 2017 Category: Respiratory Medicine Tags: Pharmacy, Pulmonology, Allergy, Journal, Source Type: news
Anti-IgE Drug Might Change Asthma Course (CME/CE)
(MedPage Today) -- Lung improvement observed in children treated with omalizumab (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - May 24, 2017 Category: Allergy & Immunology Source Type: news
omalizumab, Xolair
Title: omalizumab, XolairCategory: MedicationsCreated: 5/27/2004 12:00:00 AMLast Editorial Review: 5/15/2017 12:00:00 AM (Source: MedicineNet Asthma General)
Source: MedicineNet Asthma General - May 15, 2017 Category: Respiratory Medicine Source Type: news
FDA okays Glenmark's first-in-human study for respiratory drug
According to IMS sales data for the 12-month period ending February 2017, annual sales of XOLAIR 150 mg injection was approximately $1.7 billion in the US. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 25, 2017 Category: Pharmaceuticals Source Type: news
Xolair Tx Tied to Less Hospital Time in Young Asthmatic Kids
(MedPage Today) -- Omalizumab cut incidence of unscheduled healthcare visits for ages 6-12 years (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - November 13, 2016 Category: Allergy & Immunology Source Type: news
Omalizumab Offers Improvements in Patients with Asthma-COPD (CME/CE)
(MedPage Today) -- Better asthma control and QoL scores, but no lung function improvement (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - November 8, 2016 Category: Allergy & Immunology Source Type: news
Xolair Offers Improvements in Patients with Asthma-COPD (CME/CE)
(MedPage Today) -- Better asthma control and QoL scores, but no lung function improvement (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 8, 2016 Category: Primary Care Source Type: news
Drop-Out Rate in Omalizumab Treatment for Severe Asthma Drop-Out Rate in Omalizumab Treatment for Severe Asthma
Find out more about the omalizumab drop-out rate among patients with severe asthma. What are the common reasons for poor treatment adherence?BMC Pulmonary Medicine (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 6, 2016 Category: Allergy & Immunology Tags: Pulmonary Medicine Journal Article Source Type: news
Xolair (Omalizumab) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 18, 2016 Category: Drugs & Pharmacology Source Type: news
FDA Expands Xolair to Younger Kids With Allergic AsthmaFDA Expands Xolair to Younger Kids With Allergic Asthma
Omalizumab is now indicated in children as young as age 6 years with uncontrolled moderate to severe persistent allergic asthma. FDA Approvals (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 11, 2016 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Alert Source Type: news
